Below are the most recent publications written about "Pseudomonas aeruginosa" by people in Profiles.
-
Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, Motyl MR, Hawser SP, Sahm DF. In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020. J Med Microbiol. 2023 Feb; 72(2).
-
Lob SH, Hawser SP, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland-SMART 2017-2020. Eur J Clin Microbiol Infect Dis. 2023 Mar; 42(3):365-370.
-
Humphries RM, Janssen H, Hey-Hadavi JH, Hackel M, Sahm D. Multidrug-resistant Gram-negative bacilli recovered from respiratory and blood specimens from adults: the ATLAS surveillance program in European hospitals, 2018-2020. Int J Antimicrob Agents. 2023 Feb; 61(2):106724.
-
Karlowsky JA, Hackel MA, Wise MG, Six DA, Uehara T, Daigle DM, Cusick SM, Pevear DC, Moeck G, Sahm DF. In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrob Agents Chemother. 2023 01 24; 67(1):e0128122.
-
Lob SH, Estabrook MA, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020. Int J Infect Dis. 2022 Dec; 125:250-257.
-
Lokareddy RK, Hou CD, Doll SG, Li F, Gillilan RE, Forti F, Horner DS, Briani F, Cingolani G. Terminase Subunits from the Pseudomonas-Phage E217. J Mol Biol. 2022 10 30; 434(20):167799.
-
Karlowsky JA, Lob SH, DeRyke CA, Hilbert DW, Wong MT, Young K, Siddiqui F, Motyl MR, Sahm DF. In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020. Antimicrob Agents Chemother. 2022 05 17; 66(5):e0018922.
-
Karlowsky JA, Bouchillon SK, Benaouda A, Soraa N, Zerouali K, Mohamed N, Alami T, Sahm DF. Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020. J Glob Antimicrob Resist. 2022 09; 30:23-30.
-
Karlowsky JA, Lob SH, Khan A, Chen WT, Woo PCY, Seto WH, Ip M, Leung S, Wong QW, Chau RWY, DeRyke CA, Young K, Motyl MR, Sahm DF. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019. J Med Microbiol. 2022 Apr; 71(4).
-
Simner PJ, Musser KA, Mitchell K, Wise MG, Lewis S, Yee R, Bergman Y, Good CE, Abdelhamed AM, Li H, Laseman EM, Sahm D, Pitzer K, Quan J, Walker GT, Jacobs MR, Rhoads DD. Multicenter Evaluation of the Acuitas AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates. J Clin Microbiol. 2022 03 16; 60(3):e0209821.